Breast Cancer Clinical Trial
Digital Mammography Screening Trial (ACRIN6652)
Summary
RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for cancer. It is not yet known which type of mammography is more effective in detecting breast cancer.
PURPOSE: Screening and diagnostic trial to compare the effectiveness of two types of mammography in detecting breast cancer in women.
Full Description
OBJECTIVES:
Compare the diagnostic performance of digital mammography vs screen-film mammography, as measured by the area under the Receiver Operating Characteristic (ROC) curve, sensitivity, specificity, and positive and negative predictive values, in the detection of breast cancer in women.
Compare the diagnostic accuracy of the digital mammogram obtained using each of the individual manufacturer's digital units vs screen-film mammography through retrospective reader studies.
Determine the effects of patient characteristics, including age, lesion type, pathologic diagnosis, menopausal and hormonal status, breast density, and family history, on diagnostic accuracy of digital mammography.
Determine the effects of technical parameters, including display type, machine type, and detector spatial and contrast resolution, on diagnostic accuracy of digital mammography.
Determine the effect of reduced false-positive mammograms that are expected with digital mammography on the health-related quality of life and personal anxiety of women undergoing this screening experience.
Compare the diagnostic performance of digital mammography with the rate of cancer in a set of cases through a retrospective reader study.
Compare the effect of softcopy vs printed film display on the diagnostic performance of digital mammography through a retrospective reader study.
Compare the effect of breast density on the diagnostic accuracy of digital mammography vs screen-film mammography through a retrospective reader study.
Compare the image quality and breast radiation dose in digital vs screen-film mammography in these participants.
Determine the temporal variations in image quality, breast radiation dose, and other quality control parameters in the participating study centers.
OUTLINE: This is a randomized, multicenter study. Participants with postitive screening results are stratified according to age (under 50 vs 50-59 vs 60-70 vs over 70). Participants are randomized to one of two treatment arms.
Arm I: Participants undergo a two-view screen-film mammogram followed by a two-view digital mammogram of each breast.
Arm II: Participants undergo a two-view digital mammogram followed by a two-view screen-film mammogram of each breast.
Quality of life is assessed before the screening mammogram in the first 800 women enrolled. In an additional 1,200 participants (600 with positive screening results and 600 with negative screening results), quality of life is assessed shortly after the screening mammogram and at 1 year.
Participants are followed at 1 year with a repeat screen-film or digital mammogram.
PROJECTED ACCRUAL: A total of 49,500 participants (24,750 per arm) will be accrued for this study within 18 months.
Eligibility Criteria
4.1 Inclusion Criteria 4.1.1 All consecutive women presenting for screening mammography at the participating institutions will be eligible.
4.1.2 Signed study-specific informed consent. See Appendix I. 4.2 Exclusion Criteria 4.2.1 All women who have presented with a complaint of a focal dominant lump or a bloody or clear nipple discharge.
4.2.2 All women who have breast implants. 4.2.3 Any woman who is pregnant or has reason to believe that she might be pregnant.
4.2.4 Participants who cannot, for any reason, undergo follow-up screen-film mammography at the participating institution or provide mammograms from another institution for review for one year after study entry.
4.2.5 All women with a history of breast cancer treated with lumpectomy. Note: Women with a history of breast cancer treated with mastectomy who have now returned to a screening population will still be included in the study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 32 Locations for this study
Los Angeles California, 90095, United States
Sacramento California, 95817, United States
Aurora Colorado, 80010, United States
Washington, D.C. District of Columbia, 20037, United States
Tampa Florida, 33612, United States
Atlanta Georgia, 30322, United States
Chicago Illinois, 60610, United States
Chicago Illinois, 60637, United States
La Grange Illinois, 60525, United States
Iowa City Iowa, 52242, United States
Baltimore Maryland, 21287, United States
Boston Massachusetts, 02114, United States
Boston Massachusetts, 02215, United States
Burlington Massachusetts, 01805, United States
Royal Oak Michigan, 48073, United States
Saint Louis Missouri, 63110, United States
Long Branch New Jersey, 07740, United States
Somers Point New Jersey, 08244, United States
New York New York, 10003, United States
New York New York, 10029, United States
New York New York, 10032, United States
Rochester New York, 14620, United States
Chapel Hill North Carolina, 27599, United States
Cincinnati Ohio, 45267, United States
Philadelphia Pennsylvania, 19104, United States
Philadelphia Pennsylvania, 19107, United States
Pittsburgh Pennsylvania, 15212, United States
Providence Rhode Island, 02908, United States
Dallas Texas, 75390, United States
Charlottesville Virginia, 22908, United States
Seattle Washington, 98112, United States
North York Ontario, M4N 3, Canada
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.